Coronavirus (COVID-19) News
Filter News
Found 2,615 articles
-
Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan
9/28/2022
Ocugen, Inc. announced that the company has entered into an exclusive license agreement with Washington University in St. Louis, MO for the rights to develop, manufacture and commercialize its proprietary, intranasally delivered COVID-19 vaccine in the United States, Europe, and Japan.
-
Nykode Therapeutics Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate
9/27/2022
Nykode Therapeutics ASA announced positive clinical results from the Phase 1/2 open label, dose escalation trial of Nykode’s T cell focused pan-SARS-CoV-2 vaccine candidate in healthy individuals who were previously vaccinated with an approved mRNA vaccine.
-
Government of Canada to remove COVID-19 border and travel measures effective October 1
9/26/2022
Since the beginning of the pandemic, the Government of Canada has taken a layered approach to border management to protect the health and safety of Canadians.
-
This week, researchers delivered insights and breakthroughs in regenerative medicine, Long COVID, immuno-oncology and inflammatory diseases.
-
Pres. Joe Biden declared the COVID-19 pandemic over. Biopharma stocks react as vaccines and antivirals are still in development.
-
Moat Biotechnology Forms To Develop Novel Mucosal Vaccines for Covid-19 and Beyond: Announces Initial Funding Round and Promising Phase I trial results for Intranasal Covid-19 Vaccine
9/20/2022
Moat Biotechnology Corporation announces promising initial Phase I trial results of an intranasal COVID-19 vaccine, and kicks off an initial round of funding with lead investor Cortado Ventures.
-
Clover’s COVID-19 Vaccine Candidate Receives European Union GMP Certificate
9/20/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, announced that Clover’s contract development and manufacturing organization has received a European Union Good Manufacturing Practice certificate for the production of Clover’s lead COVID-19 vaccine candidate, SCB-2019.
-
Therma Bright Receives Payment for Initial Venowave Sales
9/20/2022
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that the initial order of its updated Venowave product has been sold to customers in the US by our exclusive distributor, DME Authority.
-
The Lancet Commission published a lengthy criticism of the WHO’s COVID-19 pandemic response. In turn, the WHO offered a reply to a number of the complaints.
-
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
9/16/2022
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion to extend the indication of Veklury® for the treatment of pediatric patients who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19 and pediatric patients with SARS-CoV-2 with pneumonia who require supplemental oxygen.
-
Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA
9/14/2022
Revive Therapeutics Ltd. announced that it has filed an amended protocol to the U.S. Food & Drug Administration for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
-
Innovative Health Diagnostics Announces New Direct-to-Consumer Tests in Women’s Health and COVID-19
9/13/2022
Innovative Health Diagnostics, a CLIA- and FDA-certified lab that empowers every person by providing access to accurate, clinical testing when and where it matters most, announced that it now offers two at-home diagnostic tests for public purchase online.
-
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
9/12/2022
Pfizer Inc. and BioNTech SE announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine has been recommended for conditional marketing authorization by the European Medicines Agency’s Committee for Medicinal Products for Human Use for individuals ages 12 years and older.
-
COMIRNATY, Pfizer-BioNTech COVID-19 Vaccine, Receives Health Canada Authorization for Children 6 Months to Under 5 Years of Age
9/9/2022
Pfizer Canada ULC and BioNTech SE announced that Health Canada has authorized COMIRNATY®, the companies' COVID-19 vaccine, as a three 3-μg primary series for children 6 months to less than 5 years of age.
-
A collaborative team of scientists formed The Long COVID Research Initiative to study and treat those battling the long-term effects of the virus, which include serious mental and physical symptoms.
-
MicroGEM and Workflow Services by ImageMover Join Forces to Provide a Comprehensive Solution for Fast Saliva PCR SARS-CoV-2 Testing at the Point of Care
9/6/2022
MicroGEM, a Virginia-based life sciences and molecular diagnostics company,and Workflow Services by ImageMover, a healthcare software company that provides solutions to capture point-of-care medical data through provider-focused digital workflows, have announced their partnership to streamline COVID-19 test result workflow.
-
SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile
9/6/2022
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute approved a phase II clinical trial for its inactivated Omicron strain COVID-19 vaccine and trivalent COVID-19 vaccine on August 31st.
-
Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases
9/6/2022
Valneva SE, a specialty vaccine company, announces that The Lancet Infectious Diseases, a peer-reviewed medical journal, has published the Company’s pivotal Phase 3 clinical data for its inactivated, whole-virus COVID-19 vaccine, VLA2001.
-
Clover’s COVID-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine
9/5/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced positive data from its ongoing Phase 3 study evaluating Clover’s SCB-2019 as a universal COVID-19 booster vaccine candidate.
-
Nanomix Announces Agreement with Mobility Health to Co-Develop a Lab Development Test for Evaluating Levels of COVID-19 Circulating Antibodies
9/2/2022
Nanomix Corporation, a leader in the development of mobile, affordable, point-of-care diagnostics, announced an agreement with Mobility Health, whereby Nanomix and Mobility Health plan to collaborate in the development of an LDT that can be deployed in a fully mobile lab to evaluate levels of circulating antibodies to COVID-19.